A trial was performed in patients with epithelioid sarcomas (nearly all tumors have homozygous deletion of SMARCB1), which demonstrated a response rate of 15%, and of the patients who responded, 67% had a response lasting 6 months or longer [68]. The gene discussed is SMARCB1; the disease is epithelioid sarcoma.